Research & Development: Page 31

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Effective Design and Implementation of Sponsor/CRO Governance — Reducing Risk While Enhancing Transparency

    Governance board meetings have always been an important venue to ensure quality and maintain a healthy and productive relationship between sponsors and CROs. As the demands of the clinical research industry continue to evolve with a pandemic now amongst us, the need for effective program governan...

    By Melissa Mauriber • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Virtual Trials: The Silver Lining of the COVID-19 Pandemic

    Many of us are identifying the proverbial silver linings associated with the changes we have been forced to make in response to the COVID-19 pandemic. One rather sweeping silver lining is the increased and accelerated use of technology in both our business and personal lives, with an obvious exam...

    By Jim Mahon • June 1, 2020
  • cancer healthcare Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    How COVID-19 Changed the Way We Recruit

    Amplifying the need for a new era of strategic patient recruitment and retention. The need for rapid and adaptive recruiting strategies has never been more urgent than in response to COVID-19. This pandemic is pushing those working to develop new treatments to pursue more agile and innovative str...

    By Erica Prowisor • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Real-World Data for R&D

    Developing a much-needed new therapeutic, maybe even for Covid 19? Seeking approval to expand labeling for an existing treatment? Wanting to understand the standard of care, design a trial, create a comparator cohort, identify a new biomarker, or model patients most likely to benefit from a parti...

    By Richard Gilklich • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Leveraging Remote Monitoring to Increase Safety, Results and Efficiencies During the Pandemic and Beyond

    In 2020, the phrase “clinical trial solutions" takes on a new — and more relevant — meaning than ever before. The world needs a solution to the global COVID-19 pandemic, and we in the life-sciences industry can contribute to that solution through innovative, state-of-the-art technology that enabl...

    By Gergory T. Simpson • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Age of the Machine: Using Algorithms to Advance Outcomes

    Machine learning is being applied across the industry to support decision-making in clinical trials, R&D, regulatory, and commercial processes. What’s the difference between machine learning and artificial intelligence? The answer lies in the word intelligence, since AI is about enabling mach...

    By Kim Ribbink • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Executive Perspective: Transforming the Clinical Experience As a Digital Care Option for Patients — A New Age of Care

    A Conversation with MaryAnne Rizk, Ph.D. For MaryAnne Rizk, Ph.D., Senior VP, Digital R&D Strategy at IQVIA, improving the patient experience is more than a calling; it’s a passion. She is driven by an inherent desire to improve the quality of life for patients. Her particular area of experti...

    By Mary Ann Rizk • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    The sequelae The personal, economic, and cultural upheaval from the coronavirus tragedy has changed our lives. The numbers, which during the early days of reported cases were abstract for most of us, have taken on new meaning in the subsequent months, as most of us now know someone who has contra...

    By Taren Grom • May 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Changing Health Outcomes with Digital Twins

    While the digital twin is not yet widely used in the pharmaceutical industry, the concept has huge potential across R&D and manufacturing. A decades-old technology is coming of age in the life-sciences industry, bringing with it the potential to solve many of the challenges companies continue...

    By Kim Ribbink • May 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Women of Influence

    Leaders become great, not because of their power, but because of their ability to empower others – John Maxwell More than two dozen women who sit in seats of influence are using their talents, strategic acumen, and tenacity to create change throughout the life-sciences industry and their organiza...

    By PharmaVoice Team • April 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Teva and Direct Relief Partner to Bring Cancer Medicines to Africa Global HOPE (Hematology-Oncology Pediatric Excellence), a program of Texas Children’s Hospital, Teva Pharmaceutical Industries, and Direct Relief are partnering to provide access to medications in sub-Saharan Africa, where a major...

    By PharmaVoice Team • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Patient-Enhanced Drug Discovery and Development

    Patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation. In other industries, it would seem odd not to get input from the end user of a product throughout the development stages. But it seems that pharmaceutical companies — some ...

    By Taren Grom • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Patient Relationships: Physicians and Payers

    Patients are taking an active role in developing relationships with all stakeholders within their healthcare environment. Over the past several years, the relationship between pharma companies and patients has garnered much of the industry’s attention. But as patients become more empowered, engag...

    By Robin Robinson • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    SHOWCASE: Real-World Evidence Comes of Age

    Whether for product development, to support clinical trial designs, for regulatory compliance, or for commercial purposes, real-world data and real-world evidence are helping to transform pharmaceutical decision-making. The legal and regulatory environment is supportive of real-world data (RWD) a...

    By PharmaVoice Team • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Ask the Experts: How Does Real World Evidence Ensure Market Access?

    Our healthcare system has experienced a fundamental shift in stakeholders’ perceptions of product value and evidentiary thresholds to demonstrate comparative effectiveness, as well as a willingness by relevant decision makers to pay. This value-and-evidence-based landscape is now relying heavily ...

    By Laura Clark • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    RWE is the Future of Clinical Research: Time to Get Onboard

    We’ve been talking about the value of real-world evidence (RWE) for years. A myriad of new data sources is being developed and linked, and a core set of analytic tools are coming into use. We now see real-world data running the gamut from patient-generated data collected through wearables and soc...

    By Nancy A. Dreyer • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    A Different Kind of Real-World Evidence: The Key Role That Patient-Provider Dialogue Research Can Play

    All roads in healthcare lead to and from the medical visit. Well, maybe not all roads, but nearly all. The medical visit is central to the overarching healthcare structure and it is driven by the dialogue between patient and provider. The healthcare data and research landscape has been changing s...

    By Katy Hewett • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Clinical Educators Provide Support Along the Whole Patient Journey

    Team Power The teams of clinical educators at VMS BioMarketing are driven to help patients on a one-to-one basis to manage chronic illnesses — in the field or on the phone each day. Taking A Step-Wise Approach to clinical education There is one club that no one wants to join, but for those who wo...

    By Clinical Educator Teams • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Executive Perspective: What Clinical technology Can Learn from Electronic Health Records

    The future of clinical technology encompasses both better adoption of simple solutions and a slower evolution toward new technologies with the focus on the patient at the center. Mike Nolte CEO, Signant Health Early in the adoption of electronic health records (EHRs), some technology leaders reco...

    By Mike Nolte • March 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    What’s old is new again This month’s cover story addresses an interesting take on science, or rather repurposing scientific R&D in a different way. For a whole host of reasons — patent cliffs, increasing discovery and development costs, mergers and acquisitions — companies are becoming more s...

    By Taren Grom • Feb. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    A Potential Cure for Hepatitis B Dr. Lawrence Blatt, CEO, Aligos Therapeutics, discusses his company’s research around antisense oligonucleotides as potential therapies for chronic hepatitis B and other diseases of the liver. Despite an available vaccine, the incidence of chronic hepatitis B (HBV...

    By PharmaVoice Team • Feb. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    New Pipeline Pathways

    The industry is becoming more strategic about repurposing its existing and shelved drugs. In the 1960s it became apparent that the drug thalidomide caused horrible birth defects in babies when pregnant mothers took it to treat their nausea. It was removed from the market. However today, that same...

    By Robin Robinson • Feb. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    SHOWCASE: Rare Disease: Rare But Not Scarce: The Struggle Faced By Millions

    A single rare disease may afflict just a small number of people, but collectively up to 400 million people globally live with a rare disease. Exactly what is a rare disease? Collectively, rare isn’t scarce or infrequent. That’s the message that the organizers of Rare Disease Day 2020 are striving...

    By PharmaVoice Team • Feb. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Lessons Learned from rare Disease First Commercial Launches

    There’s nothing more exciting, and more nerve-wracking, than a new product launch — even more so when it’s a company’s first commercial launch. We’ve had the privilege of working on more than 10 first commercial launches, most of them in rare disease. As an agency partner we’ve worked with biotec...

    By Annemarie Armstrong • Feb. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    How the "Power of Why" Can Improve Adherence Rates in Rare Disease

    Best-selling author and motivational speaker, Simon Sinek, is best known for his 2009 Ted Talk challenging organizations to set aside their list of product benefits and features to focus on the core purpose of their existence. He asks, WHY are you motivated to do what you do every day? Sinek sug...

    By Kathi Hensen • Feb. 1, 2020